REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Acinetobacter baumannii complex (ABC) causes severe infections such as pneumonia and septic shock, yet therapeutic options—particularly for carbapenem‑resistant strains (CRAB)—remain scarce amid rising antimicrobial resistance. This review synthesizes the in‑vitro activity, mechanisms of action and clinical evidence behind the newly approved agents cefiderocol and sulbactam‑durlobactam, and profiles four late‑stage investigational candidates—BV‑100, cefepime‑zidebactam, zosurabalpin and OMN6—that may […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).